US regulators expand use of Boehringer/Lilly’s diabetes drug
US regulators have expanded the scope of Boehringer Ingelheim and Eli Lilly’s Synjardy to include treatment-naïve adults with type II diabetes.
Read More
Tag: Synjardy
- Laigo Bio completes final close of €17m seed financing round
- Axplora announces expansion as newest part of $60m API investment programme
- DNA Script signs SYNTAX distribution agreements with Gencell, BMS and Biostream
- Ondine’s Steriwave phase 3 trial reaches 93% enrolment milestone
- Arvinas reports strong phase 1 results for ARV-102 in Parkinson’s disease
